Less than 10% of individuals who could benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it releases its inaugural recommendations on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently obese, it is advocating for increased and just availability to GLP-1 medication.
Per estimates, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidance recognises that excess weight is a lifelong illness that can be addressed with comprehensive and continuous treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to broad access to the treatments that can aid individuals in losing considerable body mass, notes the agency.
Skinny Jab Supply Crisis
Even in the current most favorable case, the production of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.
The recommendation encourages countries and companies to increase access, through approaches like licensing agreements.
Exclusive production rights on the active ingredient – the main component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Jabs Function
These medications replicate a body's own hormone to slow digestion, reduce hunger and increase satiety so users reduce food intake.
People typically see weight reduction after several weeks of beginning the regular doses.
Studies suggests patients may see weight return a year later of discontinuing the treatment, when their typical food cravings come back.
Being above a healthy weight increases your likelihood for contracting diseases, including diabetes, heart disease, stroke, and some malignancies.
Excess weight affects people in every country and was linked to millions of deaths worldwide in 2024, as per the health agency.
